Holen Sie sich die Stockscreener-App
2.94
4.60%
0.15
Schlusskurs vom Vortag:
$2.79
Offen:
$2.84
24-Stunden-Volumen:
31,272
Relative Volume:
0.24
Marktkapitalisierung:
$49.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.05M
KGV:
-1.3674
EPS:
-2.15
Netto-Cashflow:
$-17.78M
1W Leistung:
-4.94%
1M Leistung:
-18.03%
6M Leistung:
-45.76%
1J Leistung:
-48.53%
1-Tages-Spanne:
$2.82
$2.96
1-Wochen-Bereich:
$2.65
$3.05
52-Wochen-Spanne:
$2.45
$6.48
Envveno Medical Corporation Stock (NVNO) Company Profile
Firmenname
Envveno Medical Corporation
Sektor
Branche
Telefon
949-261-2900
Adresse
70 DOPPLER, IRVINE
Vergleichen Sie NVNO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corporation
|
2.91 | 49.45M | 0 | -24.05M | -17.78M | -2.15 |
|
ABT
Abbott Laboratories
|
125.95 | 221.85B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
97.19 | 142.24B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
370.76 | 140.07B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
93.09 | 118.98B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.09 | 40.31B | 5.72B | 4.17B | 259.90M | 6.97 |
Envveno Medical Corporation Aktie (NVNO) Neueste Nachrichten
VenoValve trial shows sustained patient benefits at 24 months - MSN
Sanctuary Advisors LLC Makes New Investment in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
enVVeno Medical (NVNO) to Release Earnings on Thursday - MarketBeat
enVVeno Medical expects capital to fund company through several milestones - TipRanks
enVVeno Medical Files For Mixed Shelf Of Up To $100 MillionSEC Filing - TradingView
enVVeno Medical reports FY24 EPS ($1.27) vs. ($1.91) last year - TipRanks
NVNOEnvveno Medical Corporation Latest Stock News & Market Updates - StockTitan
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25 - Markets Insider
EnVVeno Medical Reports Fourth Quarter and Year-End 2024 Financi - News Channel Nebraska
Can enVVeno's $43M Cash Runway Carry VenoValve Through FDA Approval? Clinical Data Shows 78% Success Rate - StockTitan
enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing - ACCESS Newswire
enVVeno Medical (NVNO) Projected to Post Quarterly Earnings on Thursday - Defense World
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series - ACCESS Newswire
enVVeno Medical (NASDAQ:NVNO) Shares Up 6.4%Here's Why - MarketBeat
enVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare Conference - ACCESS Newswire
One-year data from VenoValve US pivotal trial highlighting impact on patients’ QoL presented at AVF 2025 - Venous News
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum - BioSpace
enVVeno Announces One Year Data from VenoValve U.S. Pivotal Trial - MPO-mag
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Milton Daily Standard
Can These 5 Growth Drivers Make enVVeno Medical the Next Big Thing in Venous Disease Treatment? - StockTitan
enVVeno Medical presents one-year data from VenoValve trial - TipRanks
Revolutionary Vein Treatment Shows Lasting Benefits: Will FDA Grant First-Ever Approval for Deep CVI? - StockTitan
VenoValve trial shows sustained patient benefits at 24 months By Investing.com - Investing.com South Africa
enVVeno Medical presents two-year follow-up data from VenoValve trial - TipRanks
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting - ACCESS Newswire
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference - ACCESS Newswire
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity - ACCESS Newswire
enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R) - ACCESS Newswire
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 - ACCESS Newswire
Westside Investment Management Inc. Acquires 116,650 Shares of enVVeno Medical Corporation (NASDAQ:NVNO) - MarketBeat
enVVeno Medical Corporation Announces Proposed Public Offering - ACCESS Newswire
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering - ACCESS Newswire
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website - ACCESS Newswire
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth - Yahoo Finance
enVVeno Medical Corporation (NASDAQ:NVNO) Shares Bought by Geode Capital Management LLC - Defense World
Hancock Jaffe Laboratories, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019 - Marketscreener.com
enVVeno Medical (NASDAQ:NVNO) and Sharps Technology (NASDAQ:STSS) Head to Head Survey - Defense World
Insider Buying: Francis Duhay Acquires Shares of enVVeno Medical Corp - GuruFocus.com
Envveno medical director Robert Gray buys $10,290 in shares - Investing.com India
Envveno medical director Duhay Francis buys $249,999 in stock By Investing.com - Investing.com Canada
Envveno medical director Robert Gray buys $10,290 in shares By Investing.com - Investing.com Australia
Envveno medical director Duhay Francis buys $249,999 in stock - Investing.com India
Insider Buying: Robert Gray Acquires 3,500 Shares of enVVeno Med - GuruFocus.com
enVVeno Medical Corporation (NASDAQ:NVNO) Director Purchases $10,290.00 in Stock - MarketBeat
Finanzdaten der Envveno Medical Corporation-Aktie (NVNO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):